Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis

Frontiers in Molecular Neuroscience

Volumn 7, Issue JUNE, 2014, Pages

  Dzamko, Nicolas ^a,b   Zhou, Jinxia ^a,b   Huang, Yue ^a,b   Halliday, Glenda M ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

Brain; GAK; JNK; Kinase; LRRK2; MAPK; PINK1; PLK

Indexed keywords

ALPHA SYNUCLEIN; AUXILIN; CASEIN KINASE I; CASEIN KINASE II; CYCLIN DEPENDENT KINASE 5; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE; G PROTEIN COUPLED RECEPTOR KINASE 2; G PROTEIN COUPLED RECEPTOR KINASE 3; G PROTEIN COUPLED RECEPTOR KINASE 4; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LEUCINE RICH REPEAT KINASE 2; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PHOSPHOTRANSFERASE; POLO LIKE KINASE 1; POLO LIKE KINASE 2; POLO LIKE KINASE 3; PROTEIN SERINE THREONINE KINASE; RHODOPSIN KINASE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; AUTOPHAGY; AUTOPHOSPHORYLATION; CELL SURVIVAL; DNA REPAIR; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; MISSENSE MUTATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; OLIGOMERIZATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84928499061     PISSN: 16625099     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnmol.2014.00057     Document Type: Article

References (184)

1. Abou-Sleiman, P. M., Muqit, M. M., and Wood, N. W. (2006). Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 7,207-219. doi: 10.1038/nrn1868
2. Alegre-Abarrategui, J., Ansorge, O., Esiri, M., and Wade-Martins, R. (2008). LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease. Neuropathol. Appl. Neurobiol. 34, 272-283. doi: 10.1111/j.1365-2990.2007.00888.x
3. Alvarez-Erviti, L., Rodriguez-Oroz, M. C., Cooper, J. M., Caballero, C., Ferrer, I., Obeso, J. A., et al. (2010). Chaperone-mediated autophagy markers in Parkinson disease brains. Arch. Neurol. 67, 1464-1472. doi: 10.1001/archneurol.2010.198
4. Anderson, J. P., Walker, D. E., Goldstein, J. M., De Laat, R., Banducci, K., Caccavello, R. J., et al. (2006). Phosphorylation of Ser-129 is the dominant pathologicalmod- ification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739-29752. doi: 10.1074/jbc.M600933200
5. Arawaka, S., Wada, M., Goto, S., Karube, H., Sakamoto, M., Ren, C. H., et al. (2006). The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson's disease. J. Neurosci. 26, 9227-9238. doi: 10.1523/JNEUROSCI.0341- 06.2006
6. Bayliss, J. A., and Andrews, Z. B. (2013). Ghrelin is neuroprotective in Parkinson's disease: molecular mechanisms of metabolic neuroprotection. Ther. Adv. Endocrinol. Metab. 4, 25-36. doi: 10.1177/2042018813479645
7. Beilina, A., Rudenko, I. N., Kaganovich, A., Civiero, L., Chau, H., Kalia, S. K., et al. (2014). Unbiased screen for interactors ofleucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc. Natl. Acad. Sci. U.S.A. 111,2626-2631. doi: 10.1073/pnas.1318306111
8. Bergeron, M., Motter, R., Tanaka, P., Fauss, D., Babcock, M., Chiou, S.S., et al. (2014). In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 alpha-synuclein phosphorylation in mouse brain. Neuroscience 256, 72-82. doi: 10.1016/j.neuroscience.2013.09.061
9. Biskup, S., Moore, D. J., Rea, A., Lorenz-Deperieux, B., Coombes, C. E., Dawson, V. L., et al. (2007). Dynamic and redundant regulation of LRRK2 and LRRK1 expression. BMCNeurosci. 8:102. doi: 10.1186/1471-2202-8-102
10. Blackinton, J. G., Anvret, A., Beilina, A., Olson, L., Cookson, M. R., and Galter, D. (2007). Expression of PINK1 mRNA in human and rodent brain and in Parkinson's disease. Brain Res. 1184, 10-16. doi: 10.1016/j.brainres.2007.09.056
11. Bowers, S., Truong, A. P., Ye, M., Aubele, D. L., Sealy, J. M., Neitz, R. J., et al. (2013). Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors. Bioorg. Med. Chem. Lett. 23, 2743-2749. doi: 10.1016/j.bmcl.2013.02.065
12. Braak, H., Del Tredici, K., Rub, U., De Vos, R. A., Jansen Steur, E. N., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24,197-211. doi: 10.1016/S0197-4580(02)00065-9
13. Brion, J. P., and Couck, A. M. (1995). Cortical and brainstem-type Lewy bodies are immunoreactive for the cyclin-dependent kinase 5. Am. J. Pathol. 147,1465-1476.
14. Bychkov, E. R., Gurevich, V. V., Joyce, J. N., Benovic, J. L., and Gurevich, E. V. (2008). Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementia. Neurobiol. Aging 29, 379-396. doi: 10.1016/j.neurobiolaging.2006.10.012
15. Carlsson, A. (1959). The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol. Rev. 11, 490-493.
16. Carta, A. R. (2013). PPAR-gamma: therapeutic prospects in Parkinson's disease. Curr. DrugTargets 14, 743-751. doi: 10.2174/1389450111314070004
17. Castro-Caldas, M., Carvalho, A. N., Rodrigues, E., Henderson, C. J., Wolf, C. R., Rodrigues, C. M., et al. (2012). Tauroursodeoxycholic acid prevents MPTP- induced dopaminergic cell death in a mouse model of Parkinson's disease. Mol. Neurobiol. 46, 475-486. doi: 10.1007/s12035-012-8295-4
18. Chambers, J. W., Howard, S., and Lograsso, P.V. (2013). Blocking c-Jun N-terminal kinase (JNK) translocation to the mitochondria prevents 6-hydroxydopamine- induced toxicity in vitro and in vivo. J. Biol. Chem. 288, 1079-1087. doi: 10.1074/jbc.M112.421354
19. Chambers, J.W., Pachori, A., Howard, S., Ganno, M., Hansen, D. Jr., Kamenecka, T., et al. (2011). Small molecule c-jun-N-terminal kinase (JNK) inhibitors protect dopaminergic neurons in a model of Parkinson's disease. ACS Chem. Neurosci. 2, 198-206. doi: 10.1021/cn100109k
20. Chen, L., and Feany, M. B. (2005). Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 8, 657-663. doi: 10.1038/nn1443
21. Cheong, J. K., and Virshup, D. M. (2011). Casein kinase 1:complexityin thefamily. Int. J. Biochem. Cell Biol. 43, 465-469. doi: 10.1016/j.biocel.2010.12.004
22. Cho, H. J., Liu, G., Jin, S. M., Parisiadou, L., Xie, C., Yu, J., et al. (2013). MicroRNA-205 regulates the expression of Parkinson's disease-related leucine- rich repeat kinase 2 protein. Hum. Mol. Genet. 22, 608-620. doi: 10.1093/hmg/ dds470
23. Choi, B. S., Kim, H., Lee, H. J., Sapkota, K., Park, S. E., Kim, S., et al. (2014). Celas- trol from 'Thunder God Vine' protects SH-SY5Y cells through the preservation of mitochondrial function and inhibition of p38 MAPK in a rotenone model of Parkinson's disease. Neurochem. Res. 39, 84-96. doi: 10.1007/s11064-013-1193-y
24. Choi, W. S., Yoon, S. Y., Oh, T. H., Choi, E. J., O'malley, K. L., and Oh, Y. J. (1999). Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP+- induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK. J.Neurosci. Res. 57, 86-94. doi: 10.1002/(SICI)1097-4547(19990701)57:1<86::AID- JNR9>3.0.CO;2-E
25. Chu, C. T., Levinthal, D. J., Kulich, S. M., Chalovich, E. M., and Defranco, D. B. (2004). Oxidative neuronal injury. The darkside ofERK1/2. Eur. J. Biochem. 271, 2060-2066. doi: 10.1111/j.1432-1033.2004.04132.x
26. Chu, Y., Dodiya, H., Aebischer, P., Olanow, C. W., and Kordower, J. H. (2009). Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol. Dis. 35, 385-398. doi: 10.1016/j.nbd.2009.05.023
27. Crews, L., Spencer, B., Desplats, P., Patrick, C., Paulino, A., Rockenstein, E., et al. (2010). Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS ONE 5:e9313. doi: 10.1371/journal.pone.0009313
28. Cunnington, M. S., Kay, C., Avery, P. J., Mayosi, B. M., Koref, M. S., and Keavney, B. (2009). STK39 polymorphisms and blood pressure: an association study in British Caucasians and assessment of cis-acting influences on gene expression. BMC Med. Genet. 10:135. doi: 10.1186/1471-2350-10-135
29. Dagda, R. K., Pien, I., Wang, R., Zhu, J., Wang, K. Z., Callio, J., et al. (2014). Beyond the mitochondrion: cytosolic PINK1 remodels dendrites through protein kinase J. Neurochem. 128, 864-877. doi: 10.1111/jnc.12494
30. Davies, P., Hinkle, K. M., Sukar, N. N., Sepulveda, B., Mesias, R., Serrano, G., et al. (2013). Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies. Biochem. J. 453, 101-113. doi: 10.1042/BJ20121742
31. de Carcer, G., Escobar, B., Higuero, A. M., Garcia, L., Anson, A., Perez, G., et al. (2011a). Plk5, a polo box domain-only protein with specific roles in neuron differentiationandglioblastomasuppression. Mol. Cell. Biol. 31,1225-1239. doi: 10.1128/MCB.00607-10
32. de Carcer, G., Manning, G., and Malumbres, M. (2011b). From Plk1 to Plk5: functional evolution of polo-like kinases. Cell Cycle 10, 2255-2262. doi: 10.4161/cc.10.14.16494
33. Dehay, B., Bove, J., Rodriguez-Muela, N., Perier, C., Recasens, A., Boya, P., et al. (2010). Pathogenic lysosomal depletion in Parkinson's disease. J. Neurosci. 30, 12535-12544. doi: 10.1523/JNEUROSCI.1920-10.2010
34. Delpire, E., and Austin, T. M. (2010). Kinase regulation of Na+-K+-2Cl- cotransport in primary afferent neurons. J. Physiol. 588, 3365-3373. doi: 10.1113/jphysiol.2010.190769
35. Deng, X., Choi, H. G., Buhrlage, S. J., and Gray, N. S. (2012). Leucine-rich repeat kinase 2 inhibitors: a patent review (2006-2011). Expert Opin. Ther. Pat. 22, 1415-1426. doi: 10.1517/13543776.2012.729041
36. Dulovic, M., Jovanovic, M., Xilouri, M., Stefanis, L., Harhaji-Trajkovic, L., Kravic-Stevovic, T., et al. (2014). The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro. Neurobiol. Dis. 63, 1-11. doi: 10.1016/j.nbd.2013.11.002
37. Dumitriu, A., Pacheco, C. D., Wilk, J. B., Strathearn, K. E., Latourelle, J. C., Goldwurm, S., et al. (2011). Cyclin-G-associated kinase modifies alpha-synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study. Hum. Mol. Genet. 20, 1478-1487. doi: 10.1093/hmg/ddr026
38. Dzamko, N., Deak, M., Hentati, F., Reith, A. D., Prescott, A. R., Alessi, D. R., et al. (2010). Inhibition of LRRK2 kinase activity leads to dephosphorylation ofSer(910)/Ser(935), disruption of14-3-3 binding and altered cytoplasmic localization. Biochem. J. 430, 405-413. doi: 10.1042/BJ20100784
39. Dzamko, N., and Halliday, G. M. (2013). Unlocking the secrets of LRRK2 function with selective kinase inhibitors. Future Neurol. 8, 347-357. doi: 10.2217/fnl.13.9
40. Eisenberg, E., and Greene, L. E. (2007). Multiple roles of auxilin and hsc70 in clathrin-mediated endocytosis. Traffic 8, 640-646. doi: 10.1111/j.1600-0854.2007.00568.x
41. Escobar, V. D., Kuo, Y. M., Orrison, B. M., Giasson, B. I., and Nussbaum, R. L. (2014). Transgenic mice expressing S129 phosphorylation mutations in alpha-synuclein. Neurosci. Lett. 563, 96-100. doi: 10.1016/j.neulet.2014.01.033
42. Febbraro, F., Sahin, G., Farran, A., Soares, S., Jensen, P. H., Kirik, D., et al. (2013). Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease. Neurobiol. Dis. 56, 47-58. doi: 10.1016/j.nbd.2013.03.014
43. Ferrer, I., Blanco, R., Carmona, M., Puig, B., Barrachina, M., Gomez, C., et al. (2001). Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and dementia with Lewy bodies. J. Neural. Transm. 108, 1383-1396. doi: 10.1007/ s007020100015
44. Fish, K. J., Cegielska, A., Getman, M. E., Landes, G. M., and Virshup, D. M. (1995). Isolation and characterization of human casein kinase I epsilon (CKI), a novel member of the CKI gene family. J. Biol. Chem. 270, 14875-14883. doi: 10.1074/jbc.270.25.14875
45. Fitzgerald, K., Bergeron, M., Willits, C., Bowers, S., Aubele, D. L., Goldbach, E., et al. (2013). Pharmacological inhibition of polo like kinase 2 (PLK2) does not cause chromosomal damage or result in the formation of micronuclei. Toxicol. Appl. Pharmacol. 269,1-7. doi: 10.1016/j.taap.2013.02.012
46. Fryer, L. G., Parbu-Patel, A., and Carling, D. (2002). The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J. Biol. Chem. 277, 25226-25232. doi: 10.1074/jbc.M202489200
47. Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. et al. (2002). alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. CellBiol. 4,160-164. doi: 10.1038/ncb748
48. Gandhi, S., Muqit, M. M., Stanyer, L., Healy, D. G., Abou-Sleiman, P.M., Hargreaves, et al. (2006). PINK1 protein in normal human brain and Parkinson's disease. Brain 129, 1720-1731. doi: 10.1093/brain/awl114
49. Gao, F., Chen, D., Hu, Q., and Wang, G. (2013). Rotenone directly induces BV2 cell activation via the p38 MAPK pathway. PLoS ONE 8:e72046. doi: 10.1371/journal.pone.0072046
50. Gardet, A., Benita, Y., Li, C., Sands, B. E., Ballester, I., Stevens, C., et al. (2010). LRRK2 is involved in the IFN-gamma response and host response to pathogens. J. Immunol. 185, 5577-5585. doi: 10.4049/jimmunol.1000548
51. Gasser, T. (2009). Molecular pathogenesis ofParkinson disease: insights from genetic studies. Expert Rev Mol. Med. 11:e22. doi: 10.1017/S1462399409001148
52. Giasson, B. I., Covy, J. P., Bonini, N. M., Hurtig, H. I., Farrer, M. J., Trojanowski, J. Q., et al. (2006). Biochemical and pathological characterization of Lrrk2. Ann. Neurol. 59, 315-322. doi: 10.1002/ana.20791
53. Glover, M., and O'shaughnessy, K. M. (2011). SPAK andWNK kinases: anewtarget for blood pressure treatment? Curr. Opin. Nephrol. Hypertens. 20, 16-22. doi: 10.1097/MNH.0b013e32834132bc
54. Gomez-Santos, C., Ferrer, I., Reiriz, J., Vinals, F., Barrachina, M., and Ambrosio, S. (2002). MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. Brain Res. 935, 32-39. doi: 10.1016/S0006-8993(02)02422-8
55. Greene, L. A., Levy, O., and Malagelada, C. (2011). Akt as a victim, villain and potential hero in Parkinson's disease pathophysiology and treatment. Cell Mol. Neurobiol. 31, 969-978. doi: 10.1007/s10571-011-9671-9678
56. Grenier, K., Mclelland, G. L., and Fon, E. A. (2013). Parkin- and PINK1-dependent mitophagyinneurons: will the real pathwayplease standup? Front. Neurol. 4:100. doi: 10.3389/fneur.2013.00100
57. Grunblatt, E., Mandel, S., Jacob-Hirsch, J., Zeligson, S., Amariglo, N., Rechavi, G., et al. (2004). Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J. Neural. Transm. 111, 1543-1573. doi: 10.1007/s00702-004-0212-1
58. Guerreiro, P. S., Huang, Y., Gysbers, A., Cheng, D., Gai, W. P., Outeiro, T. F., et al. (2013). LRRK2 interactions with alpha-synuclein in Parkinson's disease brains and in cell models. J. Mol. Med. (Berl.) 91, 513-522. doi: 10.1007/s00109-012- 0984-y
59. Gurevich, E. V., Tesmer, J. J., Mushegian, A., and Gurevich, V. V. (2012). G protein-coupled receptor kinases: more than just kinases and not only for GPCRs. Pharmacol. Ther. 133, 40-69. doi: 10.1016/j.pharmthera.2011.08.001
60. Halliday, G., Hely, M., Reid, W., and Morris, J. (2008). The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol. 115,409-415. doi: 10.1007/s00401-008-0344-8
61. Hassler, R. (1938).ZurPathologie derparalysis agitans unddespost-enzephalitschen Parkinsonismus. J. Psychol. Neurol. 48, 387-476.
62. Healy, D. G., Falchi, M., O'sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., et al. (2008). Phenotype, genotype, andworldwide genetic penetrance ofLRRK2- associated Parkinson's disease: a case-control study. Lancet Neurol. 7, 583-590. doi: 10.1016/S1474-4422(08)70117-0
63. Hetman, M., and Gozdz, A. (2004). Role of extracellular signal regulated kinases 1 and2in neuronal survival. Eur. J. Biochem. 271, 2050-2055.doi: 10.1111/j.1432-1033.2004.04133.x
64. Higashi, S., Biskup, S., West, A. B., Trinkaus, D., Dawson, V. L., Faull, R. L., et al. (2007). Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res. 1155, 208-219. doi: 10.1016/j.brainres.2007.04.034
65. Hongo, H., Kihara, T., Kume, T., Izumi, Y., Niidome, T., Sugimoto, H., et al. (2012). Glycogen synthase kinase-3beta activation mediates rotenone-induced cytotoxicity with the involvement of microtubule destabilization. Biochem. Biophys. Res. Commun. 426, 94-99. doi: 10.1016/j.bbrc.2012.08.042
66. Hoozemans, J. J., Van Haastert, E. S., Eikelenboom, P., De Vos, R. A., Rozemuller, J. M., and Scheper, W. (2007). Activation of the unfolded protein response in Parkinson's disease. Biochem. Biophys. Res. Commun. 354, 707-711. doi: 10.1016/j.bbrc.2007.01.043
67. Hunot, S., Vila, M., Teismann, P., Davis, R. J., Hirsch, E. C., Przedborski, S., et al. (2014). JNK-mediatedinduction of cyclooxygenase 2 is requiredfor neurodegeneration inamouse model ofParkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 101, 665-670. doi: 10.1073/pnas.0307453101
68. Inglis, K. J., Chereau, D., Brigham, E. F., Chiou, S. S., Schobel, S., Frigon, N. L., et al. (2009). Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J. Biol. Chem. 284, 2598-2602. doi: 10.1074/jbc.C800206200
69. Investigators P. S. G. P. (2007). Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 69, 1480-1490. doi: 10.1212/01.wnl.0000277648.63931.c0
70. Ishii, A., Nonaka, T., Taniguchi, S., Saito, T., Arai, T., Mann, D., et al. (2007). Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 ofhuman alpha- synuclein: Implication for alpha-synucleinopathies. FEBS Lett. 581, 4711-4717. doi: 10.1016/j.febslet.2007.08.067
71. Jaleel, M., Nichols, R. J., Deak, M., Campbell, D. G., Gillardon, F., Knebel, A., et al. (2007). LRRK2 phosphorylates moesin at threonine-558: characterization ofhow Parkinson's disease mutants affect kinase activity. Biochem. J. 405, 307-317. doi: 10.1042/BJ20070209
72. Kamal, F. A., Travers, J. G., and Blaxall, B. C. (2012). G protein-coupled receptor kinases in cardiovascular disease: why"where" matters. Trends Cardiovasc. Med. 22,213-219. doi: 10.1016/j.tcm.2012.07.023
73. Kanaoka, Y., Kimura, S. H., Okazaki, I., Ikeda, M., and Nojima, H. (1997). GAK: a cyclin G associated kinase contains a tensin/auxilin-like domain. FEBS Lett. 402, 73-80. doi: 10.1016/S0014-5793(96)01484-6
74. Kawajiri, S., Saiki, S., Sato, S., and Hattori, N. (2011). Genetic mutations and functions of PINK1. Trends Pharmacol. Sci. 32, 573-580. doi: 10.1016/j.tips.2011.06.001
75. Kett, L. R., and Dauer, W. T. (2012). Leucine-rich repeat kinase 2 for beginners: six key questions. Cold Spring Harb. Perspect. Med. 2, a009407. doi: 10.1101/cshperspect.a009407
76. Kim, J., Byun, J. W., Choi, I., Kim, B., Jeong, H. K., Jou, I., et al. (2013). PINK1 deficiency enhances inflammatory cytokine release from acutely prepared brain slices. Exp. Neurobiol. 22, 38-44. doi: 10.5607/en.2013.22.1.38
77. Knippschild, U., Gocht, A., Wolff, S., Huber, N., Lohler, J., and Stoter, M. (2005). The casein kinase 1 family: participation in multiple cellular processes in eukaryotes. Cell. Signal. 17, 675-689. doi: 10.1016/j.cellsig.2004.12.011
78. Kondapalli, C., Kazlauskaite, A., Zhang, N., Woodroof, H. I., Campbell, D. G., Gourlay, R., et al. (2012). PINK1 is activated bymitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. Open Biol. 2, 120080. doi: 10.1098/rsob.120080.
79. Kozikowski, A. P., Gaisina, I. N., Petukhov, P. A., Sridhar, J., King, L. T., Blond, S. Y., et al. (2006). Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease. Chem. Med. Chem. 1, 256-266. doi: 10.1002/cmdc.200500039
80. Kulich, S. M., and Chu, C. T. (2001). Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease. J. Neurochem. 77,1058-1066. doi: 10.1046/j.1471-4159.2001.00304.x
81. Kyriakis, J. M., andAvruch, J. (2012). Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol. Rev. 92, 689-737. doi: 10.1152/physrev.00028.2011
82. Laplante, M., and Sabatini, D. M. (2012). mTOR signaling in growth control and disease. Cell 149, 274-293. doi: 10.1016/j.cell.2012.03.017
83. Lee, D. W., Zhao, X., Yim, Y. I., Eisenberg, E., and Greene, L. E. (2008). Essential role of cyclin-G-associated kinase (Auxilin-2) in developing and mature mice. Mol. Biol. Cell 19,2766-2776. doi: 10.1091/mbc.E07-11-1115
84. Lee, H. J., and Chung, K. C. (2012). PINK1 positively regulates IL-1beta-mediated signaling through Tollip and IRAK1 modulation. J. Neuroinflammation 9, 271. doi: 10.1186/1742-2094-9-271
85. Lee, K. W., Im, J. Y., Woo, J. M., Grosso, H., Kim, Y. S., Cristovao, A. C., et al. (2013).Neuroprotectiveandanti-inflammatorypropertiesofacoffeecomponent in the MPTP model of Parkinson's disease. Neurotherapeutics 10, 143-153. doi: 10.1007/s13311-012-0165-2
86. Li, X., Geng, J., and Liu, J. (2014). Adiponectin offers protection against L166P mutant DJ-1-induced neuronal cytotoxicity mediated by APPL1-dependent AMPK activation. Int. J. Neurosci. 124, 350-361. doi: 10.3109/00207454.2013.846340
87. Liao, J., Wu, C.X., Burlak, C., Zhang, S., Sahm, H., Wang, M., et al. (2014). Parkinson disease-associated mutation R1441H in LRRK2 prolongs the "active state" of its GTPase domain. Proc. Natl. Acad. Sci U.S.A. doi: 10.1073/pnas.1323285111.
88. Lill, C. M., Roehr, J. T., Mcqueen, M. B., Kavvoura, F. K., Bagade, S., Schjeide, B. M., et al. (2012). Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database. PLoS Genet. 8:e1002548. doi: 10.1371/journal.pgen.1002548
89. Liu, K., Shi, N., Sun, Y., Zhang, T., and Sun, X. (2013). Therapeutic effects of rapamycin on MPTP-induced Parkinsonism in mice. Neurochem. Res. 38, 201207. doi: 10.1007/s11064-012-0909-8
90. Liu, P., Wang, X., Gao, N., Zhu, H., Dai, X., Xu, Y., et al. (2010). G protein-coupled receptor kinase 5, overexpressed in the alpha-synuclein up-regulation model of Parkinson's disease, regulates bcl-2 expression. Brain Res. 1307, 134-141. doi: 10.1016/j.brainres.2009.10.036
91. Liu, X., Cheng, R., Verbitsky, M., Kisselev, S., Browne, A., Mejia-Sanatana, H., et al. (2011). Genome-wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population. BMC Med. Genet. 12:104. doi: 10.1186/1471-2350-12-104
92. Lue, L. F., Walker, D. G., Adler, C. H., Shill, H., Tran, H., Akiyama, H., et al. (2012). Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies. Brain Pathol. 22, 745-756. doi: 10.1111/j.1750- 3639.2012.00585.x
93. Lynch-Day, M. A., Mao, K., Wang, K., Zhao, M., and Klionsky, D. J. (2012). The role of autophagy in Parkinson's disease. Cold SpringHarb. Perspect. Med. 2, a009357. doi: 10.1101/cshperspect.a009357
94. Malagelada, C., Jin, Z.H., and Greene, L.A. (2008). RTP801 is inducedinParkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. J. Neurosci. 28, 14363-14371. doi: 10.1523/JNEUROSCI.3928-08.2008
95. Mandel, S. A., Sagi, Y., and Amit, T. (2007). Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway. Neurochem. Res. 32, 1694-1699. doi: 10.1007/s11064-007-9351-8
96. Matsuda, N., Sato, S., Shiba, K., Okatsu, K., Saisho, K., Gautier, C. A., et al. (2010). PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondriaandactivateslatentParkinformitophagy. J. CellBiol. 189,211-221. doi: 10.1083/jcb.200910140
97. Mbefo, M. K., Paleologou, K. E., Boucharaba, A., Oueslati, A., Schell, H., Fournier, M., et al. (2010). Phosphorylation of synucleins by members of the Polo-like kinase family. J. Biol. Chem. 285,2807-2822. doi: 10.1074/jbc.M109.081950
98. McFarland, N. R., Fan, Z., Xu, K., Schwarzschild, M. A., Feany, M. B., Hyman, T., et al. (2009). Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J. Neuropathol. Exp. Neurol. 68, 515-524. doi: 10.1097/NEN.0b013e3181a24b53
99. Meggio, F., and Pinna, L. A. (2003). One-thousand-and-one substrates of protein kinase CK2? FASEB J. 17, 349-368. doi: 10.1096/fj.02-0473rev
100. Melrose, H. L., Kent, C. B., Taylor, J. P., Dachsel, J. C., Hinkle, K. M., Lincoln, S. J., et al. (2007). A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 147, 1047-1058. doi: 10.1016/j.neuroscience.2007.05.027
101. Miklossy, J., Arai, T., Guo, J. P., Klegeris, A., Yu, S., Mcgeer, E. G., et al. (2006). LRRK2 expression in normal and pathologic human brain and in human cell lines. J. Neu- ropathol. Exp. Neurol. 65, 953-963. doi: 10.1097/01.jnen.0000235121.98052.54
102. Moehle, M. S., Webber, P. J., Tse, T., Sukar, N., Standaert, D. G., Desilva, T. M., et al. (2012). LRRK2 inhibition attenuates microglial inflammatory responses. J. Neurosci. 32, 1602-1611. doi: 10.1523/JNEUROSCI.5601-11.2012
103. Morales-Garcia, J. A., Susin, C., Alonso-Gil, S., Perez, D. I., Palomo, V., Perez, C., et al. (2013). Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. ACS Chem. Neurosci. 4, 350-360. doi: 10.1021/cn300182g
104. Moreno, J.A., Halliday, M., Molloy, C., Radford, H., Verity, N., Axten, J.M., et al. (2013). Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Sci. Transl. Med. 5, 206ra138. doi: 10.1126/scitranslmed.3006767
105. Nagao, M., and Hayashi, H. (2009). Glycogen synthase kinase-3beta is associated with Parkinson's disease. Neurosci. Lett. 449, 103-107. doi: 10.1016/j.neulet.2008.10.104
106. Nakamura, S., Kawamoto, Y., Nakano, S., Akiguchi, I., and Kimura, J. (1997). p35nck5a and cyclin-dependent kinase 5 colocalize in Lewybodies ofbrains with Parkinson's disease. Acta Neuropathol. 94,153-157. doi: 10.1007/s004010050687
107. Nalls, M. A., Plagnol, V., Hernandez, D. G., Sharma, M., Sheerin, U. M., Saad, M., et al. (2011). Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 377, 641-649. doi: 10.1016/S0140-6736(10)62345-8.
108. Narendra, D. P., Jin, S. M., Tanaka, A., Suen, D. F., Gautier, C.A., Shen, J., et al. (2010). PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol. 8:e1000298. doi: 10.1371/journal.pbio.1000298
109. Newhouse, K., Hsuan, S. L., Chang, S. H., Cai, B., Wang, Y., and Xia, Z. (2004). Rotenone-induced apoptosis is mediated by p38 and JNK MAP kinases in human dopaminergic SH-SY5Y cells. Toxicol. Sci. 79, 137-146. doi: 10.1093/toxsci/kfh089
110. Okochi, M., Walter, J., Koyama, A., Nakajo, S., Baba, M., Iwatsubo, T., et al. (2000). Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J. Biol. Chem. 275, 390-397. doi: 10.1074/jbc.275.1.390
111. Olanow, C. W., and Brundin, P. (2013). Parkinson's disease and alpha synu- clein: is Parkinson's disease a prion-like disorder? Mov. Disord. 28, 31-40. doi: 10.1002/mds.25373
112. Oueslati, A., Fournier, M., and Lashuel, H. A. (2010). Role of post-translational modifications in modulating the structure, function and toxicity of alpha- synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog. BrainRes. 183, 115-145. doi: 10.1016/S0079-6123(10)83007-9
113. Oueslati, A., Schneider, B. L., Aebischer, P., and Lashuel, H. A. (2013). Polo-like kinase 2 regulates selective autophagic alpha-synuclein clearance and suppresses its toxicity in vivo. Proc. Natl. Acad. Sci. U.S.A. 110, E3945-E3954. doi: 10.1073/pnas.1309991110
114. Paisan-Ruiz, C. (2009). LRRK2 gene variation and its contribution to Parkinson disease. Hum. Mutat. 30, 1153-1160. doi: 10.1002/humu.21038
115. Paisan-Ruiz, C., Jain, S., Evans, E. W., Gilks, W. P., Simon, J., Van Der Brug, M., et al. (2004). Cloning of the gene containing mutations that cause PARK8- linked Parkinson's disease. Neuron 44, 595-600. doi: 10.1016/j.neuron.2004.10.023
116. Pan, T., Rawal, P., Wu, Y., Xie, W., Jankovic, J., and Le, W. (2009). Rapamycin protects against rotenone-induced apoptosis through autophagy induction. Neuroscience 164, 541-551. doi: 10.1016/j.neuroscience.2009.08.014
117. Pankratz, N., Wilk, J. B., Latourelle, J. C., Destefano, A. L., Halter, C., Pugh, E. W., et al. (2009). Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum. Genet. 124, 593-605. doi: 10.1007/s00439- 008-0582-9
118. Perez, D. I., Gil, C., and Martinez, A. (2011). Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. Med. Res. Rev. 31, 924-954. doi: 10.1002/med.20207
119. Persu, A., and Vikkula, M. (2011). A genome-wide association study-derived candidate gene seeks replication: STK39. J. Hypertens. 29, 434-436. doi: 10.1097/HJH.0b013e328344b6b3
120. Peters, J. M., Mckay, R. M., Mckay, J. P., and Graff, J. M. (1999). Casein kinase I transduces Wnt signals. Nature 401, 345-350. doi: 10.1038/43830
121. Pihlstrom, L., and Toft, M. (2011). Genetic variability in SNCA and Parkinson's disease. Neurogenetics 12, 283-293. doi: 10.1007/s10048-011-0292-7
122. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047. doi: 10.1126/science.276.5321.2045
123. Pronin, A. N., Morris, A. J., Surguchov, A., and Benovic, J. L. (2000). Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 275, 26515-26522. doi: 10.1074/jbc.M003542200
124. Qing, H., Zhang, Y., Deng, Y., Mcgeer, E. G., and Mcgeer, P. L. (2009). Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease. Biochem. Biophys. Res. Commun. 390, 1229-1234. doi: 10.1016/j.bbrc.2009.10.126
125. Qu, D., Rashidian, J., Mount, M. P., Aleyasin, H., Parsanejad, M., Lira, A., et al. (2007). Role of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson's disease. Neuron 55, 37-52. doi: 10.1016/j.neuron.2007.05.033
126. Recasens, A., Dehay, B., Bove, J., Carballo-Carbajal, I., Dovero, S., Perez-Villalba, A., et al. (2014). Lewybodyextracts from Parkinson disease brains trigger alpha- synuclein pathologyand neurodegeneration in mice and monkeys. Ann. Neurol. 75, 351-362. doi: 10.1002/ana.24066
127. Rhodes, S. L., Sinsheimer, J. S., Bordelon, Y., Bronstein, J. M., and Ritz, B. (2011). Replication of GWAS associations for GAK and MAPT in Parkinson's disease. Ann. Hum. Genet. 75, 195-200. doi: 10.1111/j.1469-1809.2010.00616.x
128. Richardson, C., and Alessi, D. R. (2008). The regulation of salt transport and blood pressure bytheWNK-SPAK/OSR1 signalling pathway. J. CellSci. 121, 3293-3304. doi: 10.1242/jcs.029223
129. Ries, V., Henchcliffe, C., Kareva, T., Rzhetskaya, M., Bland, R., During, M. J., et al. (2006). Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 103, 18757-18762. doi: 10.1073/pnas.0606401103
130. Rodrigues E Silva, A. M., Geldsetzer, F., Holdorff, B., Kielhorn, F. W., Balzer-Geldsetzer, M., Oertel, W. H., et al. (2010). Who was the man who discovered the"Lewybodies"? Mov Disord. 25,1765-1773. doi: 10.1002/mds.22956
131. Rozeboom, A. M., and Pak, D. T. (2012). Identification and functional characterization of polo-like kinase 2 autoregulatory sites. Neuroscience 202, 147-157. doi: 10.1016/j.neuroscience.2011.11.003
132. Rudenko, I. N., Chia, R., and Cookson, M. R. (2012a). Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? BMCMed. 10:20.doi: 10.1186/1741-7015-10-20
133. Rudenko, I. N., Kaganovich, A., Hauser, D. N., Beylina, A., Chia, R., Ding, J., et al. (2012b). The G2385Rvariant ofleucine-rich repeat kinase 2 associatedwith Parkinson's disease isapartialloss-of-functionmutation. Biochem. J. 446,99-111. doi: 10.1042/BJ20120637
134. Ryu, M. Y., Kim, D. W., Arima, K., Mouradian, M. M., Kim, S. U., and Lee, G. (2008). Localization of CKII beta subunits in Lewy bodies of Parkinson's disease. J. Neurol. Sci. 266, 9-12. doi: 10.1016/j.jns.2007.08.027
135. Sagi, Y., Mandel, S., Amit, T., andYoudim, M. B. (2007).Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol. Dis. 25, 35-44. doi: 10.1016/j.nbd.2006.07.020
136. Sakamoto, M., Arawaka, S., Hara, S., Sato, H., Cui, C., Machiya, Y., et al. (2009). Contribution of endogenous G-protein-coupled receptor kinases to Ser129 phosphorylation of alpha-synuclein in HEK293 cells. Biochem. Biophys. Res. Commun. 384, 378-382. doi: 10.1016/j.bbrc.2009.04.130
137. Salvi, M., Trashi, E., Cozza, G., Franchin, C., Arrigoni, G., and Pinna, L. A. (2012). Investigation on PLK2 and PLK3 substrate recognition. Biochim. Biophys. Acta 1824, 1366-1373. doi: 10.1016/j.bbapap.2012.07.003
138. Samaranch, L., Lorenzo-Betancor, O., Arbelo, J. M., Ferrer, I., Lorenzo, E., Irigoyen, J., et al. (2010). PINK1-linked parkinsonism is associated with Lewy body pathology. Brain 133, 1128-1142. doi: 10.1093/brain/awq051
139. Saporito, M. S., Brown, E. M., Miller, M. S., and Carswell, S. (1999). CEP-1347/KT- 7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1- methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J. Pharmacol. Exp. Ther. 288, 421-427.
140. Saporito, M. S., Thomas, B. A., and Scott, R. W. (2000). MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J. Neurochem. 75, 1200-1208. doi: 10.1046/j.1471- 4159.2000.0751200.x
141. Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., et al. (2009). Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 41, 1303-1307. doi: 10.1038/ng.485
142. Sato, H., Kato, T., and Arawaka, S. (2013). The role of Ser129 phosphorylation of alpha-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models. Rev. Neurosci. 24, 115-123. doi: 10.1515/revneuro-2012-0071
143. Schwab, C., Demaggio, A. J., Ghoshal, N., Binder, L. I., Kuret, J., and Mcgeer, P. L. (2000). Casein kinase 1 delta is associated with pathological accumulation of tau in several neurodegenerative diseases. Neurobiol. Aging 21, 503-510. doi: 10.1016/S0197-4580(00)00110-X
144. Seeburg, D. P., Pak, D., and Sheng, M. (2005). Polo-like kinases in the nervous system. Oncogene 24, 292-298. doi: 10.1038/sj.onc.1208277
145. Sharma, M., Ioannidis, J. P., Aasly, J. O., Annesi, G., Brice, A., Van Broeckhoven, C., et al. (2012). Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology 79, 659-667. doi: 10.1212/WNL.0b013e318264e353
146. Sharma, S., Bandopadhyay, R., Lashley, T., Renton, A. E., Kingsbury, A. E., Kumaran, R., et al. (2011). LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: amorphological and quantitative study. Neuropathol. Appl. Neurobiol. 37, 777-790. doi: 10.1111/j.1365-2990.2011.01187.x
147. Sheng, Z., Zhang, S., Bustos, D., Kleinheinz, T., Le Pichon, C. E., Dominguez, S. L., et al. (2012). Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci. Transl. Med. 4, 164ra161. doi: 10.1126/scitranslmed.3004485
148. Simon-Sanchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D., et al. (2009). Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41, 1308-1312. doi: 10.1038/ng.487
149. Smith, P. D., Crocker, S. J., Jackson-Lewis, V., Jordan-Sciutto, K. L., Hayley, S., Mount, M. P., et al. (2003). Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model ofParkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 100, 13650-13655. doi: 10.1073/pnas.2232515100
150. Spencer, B., Potkar, R., Trejo, M., Rockenstein, E., Patrick, C., Gindi, R., et al. (2009). Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J. Neurosci. 29, 13578-13588. doi: 10.1523/JNEUROSCI.4390-09.2009
151. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997). Alpha-synuclein in Lewy bodies. Nature 388, 839-840. doi: 10.1038/42166
152. Tabara, H., Naito, Y., Ito, A., Katsuma, A., Sakurai, M. A., Ohno, S., et al. (2011). Neonatal lethality in knockout mice expressing the kinase-dead form of the gefitinib target GAK is caused by pulmonary dysfunction. PLoS ONE 6:e26034. doi: 10.1371/journal.pone.0026034
153. Takahashi, M., Uchikado, H., Caprotti, D., Weidenheim, K. M., Dickson, D. W., Ksiezak-Reding, H., et al. (2006). Identification of G-protein coupled receptor kinase 2 in paired helical filaments and neurofibrillary tangles. J. Neuropathol. Exp. Neurol. 65, 1157-1169. doi: 10.1097/01.jnen.0000248542.82681.12
154. Taymans, J. M. (2012). The GTPase function of LRRK2. Biochem. Soc. Trans. 40, 1063-1069. doi: 10.1042/BST20120133
155. Taymans, J. M., Van Den Haute, C., and Baekelandt, V. (2006). Distribution of PINK1 and LRRK2 in rat and mouse brain. J. Neurochem. 98, 951-961. doi: 10.1111/j.1471-4159.2006.03919.x
156. Taymans, J. M., Vancraenenbroeck, R., Ollikainen, P., Beilina, A., Lobbestael, E., De Maeyer, M., et al. (2011). LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding. PLoS ONE 6:e23207. doi: 10.1371/journal.pone.0023207
157. Thomas, T., Timmer, M., Cesnulevicius, K., Hitti, E., Kotlyarov, A., and Gaestel, M. (2008). MAPKAP kinase 2-deficiency prevents neurons from cell death by reducing neuroinflammation-relevance in a mouse model of Parkinson's disease. J. Neurochem. 105, 2039-2052. doi: 10.1111/j.1471-4159.2008. 05310.x
158. Timmons, S., Coakley, M. F., Moloney, A. M., and O' Neill, C. (2009). Akt signal transduction dysfunction in Parkinson's disease. Neurosci. Lett. 467, 30-35. doi: 10.1016/j.neulet.2009.09.055
159. Ugarte, S. D., Lin, E., Klann, E., Zigmond, M. J., and Perez, R. G. (2003). Effects of GDNF on 6-OHDA-induced death in a dopaminergic cell line: modulation by inhibitors of PI3 kinase and MEK. J. Neurosci. Res. 73, 105-112. doi: 10.1002/jnr.10632
160. Ushiro, H., Tsutsumi, T., Suzuki, K., Kayahara, T., and Nakano, K. (1998). Molecular cloning and characterization of a novel Ste20-related protein kinase enriched in neurons and transporting epithelia. Arch. Biochem. Biophys. 355, 233-240. doi: 10.1006/abbi.1998.0736
161. Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M., Harvey, K., Gispert, S., et al. (2004). Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158-1160. doi: 10.1126/science.1096284
162. Walker, D. G., Lue, L. F., Adler, C. H., Shill, H. A., Caviness, J. N., Sabbagh, M. N., et al. (2013). Changes in properties of serine 129 phosphorylatedalpha-synuclein with progression ofLewy-type histopathologyin human brains. Exp. Neurol. 240, 190-204. doi: 10.1016/j.expneurol.2012.11.020
163. Wang, W., Shi, L., Xie, Y., Ma, C., Li, W., Su, X., et al. (2004). SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease. Neurosci. Res. 48, 195-202. doi: 10.1016/j.neures.2003.10.012
164. Wang, W., Yang, Y., Ying, C., Li, W., Ruan, H., Zhu, X., et al. (2007). Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity. Neuropharmacology 52, 1678-1684. doi: 10.1016/j.neuropharm.2007.03.017
165. Wang, Y., O'connell, J. R., Mcardle, P. F., Wade, J. B., Dorff, S. E., Shah, S. J., et al. (2009a). From the Cover: Whole-genome association studyidentifies STK39 as a hypertension susceptibility gene. Proc. Natl. Acad. Sci. U.S.A. 106, 226-231. doi: 10.1073/pnas.0808358106
166. Wang, Y., Zhang, Y., Wei, Z., Li, H., Zhou, H., Zhang, Z., et al. (2009b). JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson's disease. J. Neurol. Sci. 285,172-177. doi: 10.1016/j.jns.2009.06.034
167. Waxman, E. A., Covy, J. P., Bukh, I., Li, X., Dawson, T. M., and Giasson, B. I. (2009). Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions. J. Neuropathol. Exp. Neurol. 68, 785-796. doi: 10.1097/NEN.0b013e3181aaf4fd
168. Waxman, E. A., and Giasson, B. I. (2008). Specificity and regulation of casein kinase- mediated phosphorylation of alpha-synuclein. J. Neuropathol. Exp. Neurol. 67, 402-416. doi: 10.1097/NEN.0b013e31816fc995
169. Waxman, E. A., and Giasson, B. I. (2011). Characterization of kinases involved in the phosphorylation of aggregatedalpha-synuclein. J. Neurosci. Res. 89,231-247. doi: 10.1002/jnr.22537
170. West, A. B., Cowell, R. M., Daher, J. P., Moehle, M. S., Hinkle, K. M., Melrose, H. L., et al. (2014). Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents. J. Comp. Neurol. 522, Spc1. doi: 10.1002/cne.23583
171. West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., et al. (2005). Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U.S.A. 102, 16842-16847. doi: 10.1073/pnas.0507360102
172. Wills, J., Jones, J., Haggerty, T., Duka, V., Joyce, J. N., and Sidhu, A. (2010). Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp. Neurol. 225, 210-218. doi: 10.1016/j.expneurol.2010.06.017
173. Winkles, J.A., andAlberts, G. F. (2005). Differential regulation of polo-like kinase 1, 2, 3,and4geneexpressioninmammaliancellsandtissues. Oncogene 24,260-266. doi: 10.1038/sj.onc.1208219
174. Woodroof, H. I., Pogson, J. H., Begley, M., Cantley, L. C., Deak, M., Campbell, D. G., et al. (2011). Discovery of catalytically active orthologues of the Parkinson's disease kinase PINK1: analysis of substrate specificity and impact of mutations. Open Biol. 1, 110012. doi: 10.1098/rsob.110012
175. Wu, Y., Li, X., Zhu, J. X., Xie, W., Le, W., Fan, Z., et al. (2011). Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals 19, 163-174. doi: 10.1159/000328516
176. Xing, B., Liu, M., and Bing, G. (2007). Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF- kappaB and JNK activation and suppression of COX-2 activity. J. Neuroimmunol. 192, 89-98. doi: 10.1016/j.jneuroim.2007.09.029
177. Xiong, N., Jia, M., Chen, C., Xiong, J., Zhang, Z., Huang, J., et al. (2011). Potential autophagy enhancers attenuate rotenone-induced toxicity in SH-SY5Y. Neuroscience 199,292-302. doi: 10.1016/j.neuroscience.2011.10.031
178. Yan, Y., Nguyen, H., Dalmasso, G., Sitaraman, S. V., and Merlin, D. (2007). Cloning and characterization of a new intestinal inflammation-associated colonic epithelial Ste20-related protein kinase isoform. Biochim. Biophys. Acta 1769, 106-116. doi: 10.1016/j.bbaexp.2007.01.003
179. Yuskaitis, C. J., and Jope, R. S. (2009). Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell. Signal. 21, 264-273. doi: 10.1016/j.cellsig.2008.10.014
180. Zhai, A., Zhu, X., Wang, X., Chen, R., and Wang, H. (2013). Secalonic acidAprotects dopaminergic neurons from 1-methyl-4-phenylpyridinium (MPP(+))-induced cell deathviathe mitochondrialapoptoticpathway. Eur. J. Pharmacol. 713, 58-67. doi: 10.1016/j.ejphar.2013.04.029
181. Zhou, J., Broe, M., Huang, Y., Anderson, J. P., Gai, W. P., Milward, E. A., et al. (2011). Changes in the solubilityand phosphorylation of alpha-synuclein over the course ofParkinson's disease. Acta Neuropathol. 121, 695-704. doi: 10.1007/s00401-011- 0815-1
182. Zhu, J. H., Guo, F., Shelburne, J., Watkins, S., and Chu, C. T. (2003). Localization of phosphorylated ERK/MAP kinases to mitochondria and autophagosomes in Lewy body diseases. Brain Pathol. 13, 473-481 doi: 10.1111/j.1750-3639.2003.tb 00478.x
183. Zhu, J. H., Kulich, S. M., Oury, T. D., and Chu, C. T. (2002). Cytoplasmic aggregates of phosphorylated extracellular signal-regulated protein kinases in Lewy body diseases. Am. J. Pathol. 161, 2087-2098. doi: 10.1016/S0002-9440(10) 64487-2
184. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., et al. (2004). Mutations in LRRK2 cause autosomal-dominant parkinsonismwith pleomorphic pathology. Neuron 44, 601-607. doi: 10.1016/j.neuron.2004.11.005